US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Silexion Therapeutics Corp

0.8746

-0.0110-1.24%

Post-market: 0.88000.0054+0.62%19:08 EDT

Volume:138.01K

Turnover:119.03K

Market Cap:7.60M

PE:-6.48

High:0.8855

Open:0.8854

Low:0.8300

Close:0.8856

Loading ...

Overview Company News Filings

Silexion Therapeutics Is Maintained at Buy by Maxim Group

Silexion Therapeutics 2024 Net Income $(16.5)M Vs $(5.1)M In 2023

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Corp: Anticipates Sharing Initial Results From Sil-204 Study in March 2025

THOMSON REUTERS

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Dow Jumps Over 100 Points; Tesla Earnings Miss Views

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Sector Update: Health Care Stocks Decline Tuesday Afternoon

MT Newswires Live

Gold Gains 1%; Boeing Shares Rise Following Q4 Results

Silexion Therapeutics Surge in Recent Trading Amid 'Promising' Preclinical Data From Tumor Drug Candidate

MT Newswires Live

BUZZ-Silexion Therapeutics soars on preclinical cancer trial data

Silexion Therapeutics reports preclinical data for SIL-204

Silexion Therapeutics Reports Strong Tumor Growth Reduction From Systemic Administration of Sil-204 in Preclinical Pancreatic Cancer Models

THOMSON REUTERS

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Top Midday Decliners

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLXN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":0.8746,"timestamp":1749844800000,"preClose":0.8856,"halted":0,"volume":138014,"hourTrading":{"tag":"盘后","latestPrice":0.88,"preClose":0.8746,"latestTime":"19:08 EDT","volume":1617,"amount":1404.5785,"timestamp":1749856103672},"delay":0,"floatShares":5231700,"shares":8692392,"eps":-0.135024,"marketStatus":"Market Closed","change":-0.011,"latestTime":"06-13 16:00:00 EDT","open":0.8854,"high":0.8855,"low":0.83,"amount":119026.21743861999,"amplitude":0.062669,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.135024,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8856,"preHourTrading":{"tag":"盘前","latestPrice":0.8855,"preClose":0.8856,"latestTime":"09:25 EDT","volume":4189,"amount":3696.1700146,"timestamp":1749821139540},"postHourTrading":{"tag":"盘后","latestPrice":0.88,"preClose":0.8746,"latestTime":"19:08 EDT","volume":1617,"amount":1404.5785,"timestamp":1749856103672},"volumeRatio":0.6560024788735379},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5231700,"roa":"-193.54%","roe":"--","lyrEps":0.042916,"volumeRatio":0.6560024788735379,"shares":8692392,"dividePrice":0,"high":0.8855,"amplitude":0.062669,"preClose":0.8856,"low":0.83,"week52Low":0.575,"pbRate":"-1.91","week52High":122.0184,"institutionHeld":0,"latestPrice":0.8746,"eps":-0.135024,"divideRate":0,"volume":138014,"delay":0,"ttmEps":-0.135024,"open":0.8854,"prevYearClose":2.01,"prevWeekClose":0.9458,"prevMonthClose":1.04,"prevQuarterClose":1.1,"fiveDayClose":0.9458,"twentyDayClose":0.9647,"sixtyDayClose":1.11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520463053","title":"Silexion Therapeutics Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2520463053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520463053?lang=en_us&edition=fundamental","pubTime":"2025-03-20 23:11","pubTimestamp":1742483460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLXN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 11:11 ET (15:11 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","LENZ"],"gpt_icon":0},{"id":"2520326879","title":"Silexion Therapeutics 2024 Net Income $(16.5)M Vs  $(5.1)M In 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2520326879","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520326879?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:32","pubTimestamp":1742329938,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics 2024 Net Income $(16.5)M Vs  $(5.1)M In 2023","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44385979/silexion-therapeutics-2024-net-income-16-5-m-vs-5-1-m-in-2023","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","SLXN"],"gpt_icon":0},{"id":"2520834932","title":"Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520834932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520834932?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:29","pubTimestamp":1742329776,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nTUAC72RGR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2520693218","title":"Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520693218","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520693218?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:29","pubTimestamp":1742329740,"startTime":"0","endTime":"0","summary":"Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse mod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/18/3044999/0/en/Silexion-Therapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","ORR","BK4139","LENZ"],"gpt_icon":0},{"id":"2520652560","title":"PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2520652560","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520652560?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:15","pubTimestamp":1742213700,"startTime":"0","endTime":"0","summary":"Silexion's Groundbreaking Orthotopic Model Data and the Potential Expansion of its Development Plan Position SIL204 as Potential Transformative Therapy; Wall Street Maintains Buy Rating and $9 Price Target representing a signifcant premium of almost +600% over current prices; Silexion's new expanded development plan expected to be completed shortly; Precision Oncology M&A Market has heated up in recent years with a series of Multi-Billion Dollar Acquisitions in the field. NEW YORK, March 17, 2025----PESG Research releases a report covering Silexion Therapeutics’ * latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology's most challenging targets.Maxim Group has maintained its analysis of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-report-silexion-therapeutics-breakthrough-121500022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","SLXN","SLXNW","BK4139"],"gpt_icon":0},{"id":"2517914907","title":"Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2517914907","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517914907?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:30","pubTimestamp":1741181400,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic Cance","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037405/0/en/Silexion-Therapeutics-Reports-Groundbreaking-Positive-Initial-Data-from-Systemic-Administration-of-SIL204-in-Orthotopic-Pancreatic-Cancer-Models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SLXN","BK4139"],"gpt_icon":0},{"id":"2516636126","title":"PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational","url":"https://stock-news.laohu8.com/highlight/detail?id=2516636126","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516636126?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:30","pubTimestamp":1741008600,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could validate systemic efficacy against metastatic disease for the first time. Reportedly, Maxim Group maintains a $9 price target and strong buy rating, citing the company's growing clinical trajectory and RNAi platform validation. With a data readout expected this month, this could be a major catalyst for the company, as interest for innovative KRAS-targeting therapies continues to rise. The ability to target both primary and metastatic pancreatic cancer via systemic administration would represent a major breakthrough, as Silexion has not previously demonstrated this effect in metastatic models. If the orthotopic model results show significant impact on metastases, this could mark a critical validation step, potentially differentiating SIL-204 from existing KRAS-targeting approaches and opening the door to expanded clinical applications.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-industry-anticipation-rises-silexion-133000441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLXN","LENZ","SLXNW","BK4139"],"gpt_icon":0},{"id":"2514091970","title":"Silexion Therapeutics Corp:  Anticipates Sharing Initial Results From Sil-204 Study in March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514091970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514091970?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:30","pubTimestamp":1740490257,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2514094309","title":"Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204","url":"https://stock-news.laohu8.com/highlight/detail?id=2514094309","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514094309?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:30","pubTimestamp":1740490200,"startTime":"0","endTime":"0","summary":"Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks. Grand Cayman, Cayman Islands, Feb. 25, 2025  -- Silexion Therapeutics Corp.  , a clinical-stage biotechnology company pioneering RNA interference  therapies for KRAS-driven cancers, today announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This milestone represents the first systematic evaluation of SIL-204 administered subcutaneously in clinically relevant pancreatic cancer models.The study specifically evaluated two critical aspects of SIL-204's potential therapeutic profile:. SIL-204's ability to reduce primary tumor growth when administered systemically in orthotopic pancreatic cancer models, where human tumor cells are implanted directly into the pancreas. \"Completing this initial study in orthotopic models represents a significant milestone in our","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silexion-therapeutics-announces-completion-initial-133000462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLXN","SIL","BK4139","SLXNW","LENZ"],"gpt_icon":0},{"id":"2507249406","title":"Dow Jumps Over 100 Points; Tesla Earnings Miss Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2507249406","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507249406?lang=en_us&edition=fundamental","pubTime":"2025-01-30 23:03","pubTimestamp":1738249415,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/01/43340053/dow-jumps-over-100-points-tesla-earnings-miss-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLL","AMOD","CLEU","ATHE","SLXN","TSLA","TECX","CRGX","PCOM"],"gpt_icon":1},{"id":"2507661799","title":"Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2507661799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507661799?lang=en_us&edition=fundamental","pubTime":"2025-01-30 06:30","pubTimestamp":1738189800,"startTime":"0","endTime":"0","summary":"Cayman Islands, January 29, 2025 --Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017648/0/en/Silexion-Therapeutics-Announces-Exercise-of-Warrants-for-3-3-Million-Gross-Proceeds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","SLXN"],"gpt_icon":1},{"id":"2507963406","title":"PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2507963406","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507963406?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:59","pubTimestamp":1738162740,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price Target as Company Advances RNAi Platform for KRAS-Driven Cancers Amid Hot Precision Oncology M&A Market and a series of Multi-Billion Dollar Acquisitions in the field. Notable industry analysts seem to have taken notice, with Maxim Group initiating coverage with a \"strong buy\" recommendation in November 2024 and an updated price target of $9. As Silexion advances toward clinical trials with SIL-204 and explores expanded development strategies, several key catalysts may lie ahead and could be worth watching closely, including metastasis impact studies, advancement towards next phases of trials, data from additional indications, potential strategic partnerships, and more positioning the company uniquely in the precision oncology landscape at a time when the industry actively seeks innovative solutions","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-report-silexion-therapeutics-systemic-145900692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","SLXN","SLXNW","BK4139"],"gpt_icon":0},{"id":"2507542285","title":"Sector Update: Health Care Stocks Decline Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2507542285","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507542285?lang=en_us&edition=fundamental","pubTime":"2025-01-29 02:55","pubTimestamp":1738090543,"startTime":"0","endTime":"0","summary":"Health care stocks fell Tuesday afternoon with the NYSE Health Care Index shedding 0.5% and the Health Care Select Sector SPDR Fund  down 0.4%.The iShares Biotechnology ETF  was little changed, erasing earlier gains.In corporate news, Surgery Partners  shares jumped 18%. Bain Capital Partners delivered a non-binding proposal late Monday to Surgery Partners' board proposing to buy the remaining shares for $25.75 apiece in cash.Silexion Therapeutics  shares surged 79% after the company reported \"promising\" preclinical data from its tumor drug candidate, SIL-204, in mice.Trinity Biotech  shares jumped 53% after the company said the latest pre-pivotal trial for its continuous glucose monitoring technology yielded \"breakthrough\" results.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","BK4588","XLV","TRIB","BK4185","SGRY","BK4581","IBB","SLXN","BK4139","BK4585"],"gpt_icon":0},{"id":"2507054216","title":"Gold Gains 1%; Boeing Shares Rise Following Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2507054216","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507054216?lang=en_us&edition=fundamental","pubTime":"2025-01-29 02:46","pubTimestamp":1738089998,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/01/43282917/gold-gains-1-boeing-shares-rise-following-q4-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","STSS","MNQmain","BHF","LU1429558221.USD","QLD","SQQQ","LPTX","BK4139","LU2326559502.SGD","BK4187","NQmain","BK4563","BK4516","SLXN","BK4162","CR","BA",".IXIC","BK4505","BK4585","BK4161","USAW.SI","USJW.SI","QID","BK4588","BK4564","BK4198","SABS","NVIW.SI","PSQ","LU1435385759.SGD","TQQQ","BK4551"],"gpt_icon":1},{"id":"2507548449","title":"Silexion Therapeutics Surge in Recent Trading Amid 'Promising' Preclinical Data From Tumor Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2507548449","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507548449?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:15","pubTimestamp":1738080905,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics  shares rose more than 100% in recent Tuesday trading after the company reported \"promising\" preclinical data from its tumor drug candidate, SIL-204, in mice.Based on the data, the company said the drug candidate administered in an extended-release formulation reduced tumor growth by more than 50% after 30 days, with about 50% of tumors showing complete necrosis in human pancreatic tumors.The company also said that the drug candidate administered subcutaneously inhibited tumor growth in mouse metastatic pancreatic orthotopic models.\"While the current data shows robust tumor growth inhibition, further studies aim to evaluate its impact on metastases, which the Company is cautiously optimistic about,\" the company said.Silexion said it is actively exploring how the data may be used to determine an expanded treatment strategy for certain cancers and expects to announce the details of its expanded development plan \"shortly.\"Price: 1.16, Change: +0.58, Percent Change: +","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","SLXN"],"gpt_icon":0},{"id":"2506519972","title":"BUZZ-Silexion Therapeutics soars on preclinical cancer trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2506519972","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506519972?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:13","pubTimestamp":1738073629,"startTime":"0","endTime":"0","summary":"BUZZ-Silexion Therapeutics soars on preclinical cancer trial data** Shares of drug developer Silexion Therapeutics SLXN.O rise ~125% to $1.30 premarket** SLXN says preclinical trials of its cancer treatment, SIL-204, shows significant reduction in tumor growth in pancreatic cancer models** SIL-204 reduced tumor growth by 50% and showed complete necrosis in 50% of tumors in some trials** Says SIL-204 was effective in inhibiting key cancer-causing KRAS mutations and maintained effective drug levels in the body for over 56 days** SLXN fell 88.4% in 2024, since its Nasdaq debut on Aug. 16, 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nL3N3OO0ZI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2506515267","title":"Silexion Therapeutics reports preclinical data for SIL-204","url":"https://stock-news.laohu8.com/highlight/detail?id=2506515267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506515267?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:36","pubTimestamp":1738071379,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-reports-preclinical-data-for-sil-204?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-reports-preclinical-data-for-sil-204?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN","BK4139","SIL","LENZ"],"gpt_icon":0},{"id":"2506155135","title":"Silexion Therapeutics Reports Strong Tumor Growth Reduction From Systemic Administration of Sil-204 in Preclinical Pancreatic Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2506155135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506155135?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:30","pubTimestamp":1738071002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO1FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2506516350","title":"Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2506516350","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506516350?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:29","pubTimestamp":1738070940,"startTime":"0","endTime":"0","summary":"New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016377/0/en/Silexion-Therapeutics-Reports-Strong-Tumor-Growth-Reduction-from-Systemic-Administration-of-SIL-204-in-Preclinical-Pancreatic-Cancer-Models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIL","BK4139","LENZ","SLXN"],"gpt_icon":0},{"id":"2504465109","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2504465109","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504465109?lang=en_us&edition=fundamental","pubTime":"2025-01-17 02:31","pubTimestamp":1737052299,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics (ATRA) reported \"compliance issues\" on Thursday involving a third-party manufacturing facility for Ebvallo, a treatment for patients with Epstein-Barr virus-positive post-transpl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0170899867.USD","ATRA","BK4588","BK4504","BK4207","USB","IE00BFXG1179.USD","SLXN","BK4139","LU2237438978.USD","BK4585","BK4559"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":68,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730520000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2025-06-13","current":-0.453201,"percent":1,"low":-0.532214,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"high":-0.453201,"avg":-0.491464,"sd":0.020221,"marketCap":7451983},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983}],"updateTime":1749916996436}}}